IMMP - Immutep Ltd ADR

IMMP - Immutep Ltd ADR

https://www.immutep.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

GlobeNewswire • 1 week ago • score: 0.23

SYDNEY, AUSTRALIA, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Immutep Limited ( ASX: IMM. NASDAQ: IMMP ) ( "Immutep" or "the Company" ) , a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract for the EFTISARC-NEO Phase II investigator-initiated trial ...

Immutep Posts 61% Response Rate In NSCLC Trial With Keytruda Combo - Immutep ( NASDAQ:IMMP )

Benzinga • 3 months, 4 weeks ago • score: 0.13

Efti combo showed a 60.8% response rate and 90.2% disease control in 1L NSCLC. In PD-L1 negative patients, ORR reached 54.5% vs. 32.3% historical control. Don't miss this list of 3 high-yield stocks-including one delivering over 10%-built for income in today's chaotic market.

Immutep Quarterly Activities Report Q3 FY25

GlobeNewswire • 4 months, 2 weeks ago • score: 0.21

Media Release ...

Immutep to Participate in Upcoming Investor Conferences

GlobeNewswire • 5 months, 1 week ago • score: 0.27

SYDNEY, AUSTRALIA , April 02, 2025 ( GLOBE NEWSWIRE ) -- Immutep Limited ( ASX: IMM. NASDAQ: IMMP ) ( "Immutep" or "the Company" ) , a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at ...

Immutep Quarterly Activities Report Q2 FY25

GlobeNewswire • 7 months, 2 weeks ago • score: 0.16

Media Release ...

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

GlobeNewswire • 9 months ago • score: 0.01

SYDNEY, AUSTRALIA, Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- Immutep Limited ( ASX: IMM. NASDAQ: IMMP ) ( "Immutep" or "the Company" ) , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort ...

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial - Immutep ( NASDAQ:IMMP )

Benzinga • 10 months ago • score: 0.10

On Thursday, Immutep Limited IMMP released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha ( efti ) in combination with Merck & Co Inc's MRK Keytruda ( pembrolizumab ) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer ( 1L NSCLC ) ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Immutep Limited, a biotechnology company, is dedicated to the research and development of pharmaceutical candidates. The company is headquartered in Sydney, Australia.

52W High

$2.72

52W Low

$1.32

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.41

Valuation

Attractive

As of 2024-12-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

7.65

EV/EBITDA (<8 favorable)

-2.94

EV/Revenue (<3 favorable)

803.42

P/S (TTM) (<3 favorable)

48.02

P/B (<3 favorable)

2.58

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.01%

Institutions (25–75% balanced)

1.91%

Shares Outstanding

146,786,000

Float

1,228,251,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2024-12-31 (Overview)

Revenue (TTM)

5,043,800

Gross Profit (TTM)

-56,366,760

EPS (TTM)

-0.28

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-20.35%

ROE (TTM) (>15% strong)

-0.37%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.10

Momentum

Bearish momentum

Value

-0.0245

Previous

-0.0250

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025